Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

prospectively confirmed by an expert panel according to predefined criteria, will be tested for RAS and BRAF tumor mutation status and selected by location of primary tumor. Patients with RAS or BRAF mutant and

folfiri regimen
bevacizumab
panitumumab
folfox regimen
systemic therapy
  • 177 views
  • 19 Sep, 2021
  • 64 locations
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

+ ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

ipilimumab
measurable disease
ct scan
metastatic melanoma
BRAF
  • 11 views
  • 01 May, 2021
  • 52 locations
Veliparib Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from …

astrocytoma, anaplastic
malignant glioma
immunohistochemistry
glomerular filtration rate
epilepsy
  • 403 views
  • 19 Sep, 2021
  • 112 locations
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation

non-squamous non-small cell lung cancer
growth factor
pembrolizumab
measurable disease
cancer chemotherapy
  • 0 views
  • 01 Aug, 2021
  • 47 locations
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687 subjects will be randomized to one of the following treatment arms in …

bevacizumab
tipiracil
colorectal adenocarcinoma
oxaliplatin
irinotecan
  • 0 views
  • 07 Sep, 2021
  • 150 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

tipifarnib
beta human chorionic gonadotropin
myelosuppressive chemotherapy
glomerular filtration rate
MRI
  • 997 views
  • 12 Sep, 2021
  • 114 locations
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH

cobimetinib
vemurafenib
serum pregnancy test
systemic therapy
serum ldh
  • 9 views
  • 19 Sep, 2021
  • 1 location
ENCOrafenib With Binimetinib in bRAF NSCLC

A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

  • 0 views
  • 03 Feb, 2021
  • 38 locations
Encorafenib Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma. Dose escalation phase: Previously treated or treatment-nave patients will be evaluated after the

  • 0 views
  • 30 Jan, 2021
  • 1 location
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF

  • 0 views
  • 18 Mar, 2021
  • 1 location